Wilson Sonsini advised Faeth Therapeutics on the deal. Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal while Fenwick & West represented Lycia Therapeutics. Lycia Therapeutics, Inc., a leader in extracellular protein...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced the closing of...
You must be a Standard 1 Year member to access this content.
Wiersholm and Elvinger Hoss Prussen assisted Alussa Energy on the deal while Wilson Sonsini Goodrich & Rosati and Arendt have advised FREYR AS on the deal....
You must be a Standard 1 Year member to access this content.
